Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 23, 2022Frontiers in PhysiologyOpen Access

Pharmacological rescue of specific long QT variants of KCNQ1/KCNE1 channels

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Beta-blockers are the standard of care for LQT1 but act without correcting the loss-of-function of potassium channels, prompting evaluation of compounds that enhance I KS channels.

Population

I KS channels expressed in CHO cells and Xenopus oocytes

Comparison

ML277 and R-L3 vs wild type or untreated mutant channels

Design

In vitro experimental electrophysiological study

Authors

XZXinle ZouXWXiaoan WuKSKevin J. Sampson

Discussion

Loading...

Member takes

Overview

Supports mutation-specific IKS rescue for select LQT1/LQT5 variants in vitro; leaves open in vivo efficacy and clinical translation.

Structured PICO

P
Population
Chinese hamster ovary (CHO) cells and Xenopus laevis oocytes expressing wild-type and mutant KCNQ1/KCNE1 channels (LQT1 mutations KCNQ1-S546L, KCNQ1-T265I; LQT5 mutations KCNE1-L51H, KCNE1-G52R, KCNE1-D76N)
I
Intervention
ML277 (1 μM) and R-L3 (1 μM)
C
Comparator
Drug-free control conditions and wild-type IKS channels
O
Outcome
IKS current amplitude and channel deactivation kineticssurrogate

ML277 and R-L3 demonstrate potential as mutation-specific pharmacological therapies for certain LQT1 and LQT5 variants by restoring IKS channel function.

Cite This Study

Zou et al. (2022) studied this question.

synapsesocial.com/papers/6a1e3656148c35e1ed689e32https://doi.org/10.3389/fphys.2022.902224
View Full Paper
Ask AI
Bookmark
Share